{"meshTagsMajor":["Drug Resistance, Neoplasm"],"meshTags":["Protein Kinase Inhibitors","Phosphatidylinositol 3-Kinases","Antigens, CD274","Mitogen-Activated Protein Kinase Kinases","Drug Resistance, Neoplasm","Proto-Oncogene Proteins B-raf","Melanoma","Humans"],"meshMinor":["Protein Kinase Inhibitors","Phosphatidylinositol 3-Kinases","Antigens, CD274","Mitogen-Activated Protein Kinase Kinases","Proto-Oncogene Proteins B-raf","Melanoma","Humans"],"genes":["PD-L1","BRAF V600 oncogene","BRAF","BRAF"],"organisms":["9606"],"publicationTypes":["Comment","Journal Article"],"abstract":"Treatment of metastatic melanoma with inhibitors of the BRAF V600 oncogene in melanoma has been limited by the development of resistance. Combining the BRAF inhibitors with immunotherapy may prolong the response, but will acquisition of resistance to BRAF inhibitors also make melanoma cells resistant to immunotherapy?","title":"A focus on PD-L1 in human melanoma.","pubmedId":"23251000"}